WO2000010554A3 - Procedes et compositions employant le vigabatrin s(+) optiquement pur - Google Patents

Procedes et compositions employant le vigabatrin s(+) optiquement pur Download PDF

Info

Publication number
WO2000010554A3
WO2000010554A3 PCT/US1999/019346 US9919346W WO0010554A3 WO 2000010554 A3 WO2000010554 A3 WO 2000010554A3 US 9919346 W US9919346 W US 9919346W WO 0010554 A3 WO0010554 A3 WO 0010554A3
Authority
WO
WIPO (PCT)
Prior art keywords
vigabatrin
methods
optically pure
compositions employing
employing optically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/019346
Other languages
English (en)
Other versions
WO2000010554A2 (fr
Inventor
Paul D Rubin
Timothy J Barberich
William E Yelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Priority to AU57844/99A priority Critical patent/AU5784499A/en
Priority to CA002341400A priority patent/CA2341400A1/fr
Priority to EP99945177A priority patent/EP1107748A2/fr
Priority to JP2000565876A priority patent/JP2003520189A/ja
Publication of WO2000010554A2 publication Critical patent/WO2000010554A2/fr
Publication of WO2000010554A3 publication Critical patent/WO2000010554A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des procédés et compositions pour la prévention, le traitement et/ou la gestion des symptômes de neuropathie périphérique et d'affections connexes, de narcomanie ou d'alcoolisme ou leurs symptômes, ou des symptômes associés au sevrage alcoolique ou au sevrage de drogue, utilisant du vigabatrin S(+) optiquement pur, ou un sel de celui-ci pharmaceutiquement acceptable.
PCT/US1999/019346 1998-08-25 1999-08-24 Procedes et compositions employant le vigabatrin s(+) optiquement pur Ceased WO2000010554A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU57844/99A AU5784499A (en) 1998-08-25 1999-08-24 Methods and compositions employing optically pure s(+) vigabatrin
CA002341400A CA2341400A1 (fr) 1998-08-25 1999-08-24 Procedes et compositions employant le vigabatrin s(+) optiquement pur
EP99945177A EP1107748A2 (fr) 1998-08-25 1999-08-24 Procedes et compositions employant le vigabatrin s(+) optiquement pur
JP2000565876A JP2003520189A (ja) 1998-08-25 1999-08-24 光学的に純粋なｓ（＋）ビガバトリンを用いる方法および組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9778698P 1998-08-25 1998-08-25
US60/097,786 1998-08-25
US11445698P 1998-12-30 1998-12-30
US60/114,456 1998-12-30

Publications (2)

Publication Number Publication Date
WO2000010554A2 WO2000010554A2 (fr) 2000-03-02
WO2000010554A3 true WO2000010554A3 (fr) 2000-11-30

Family

ID=26793638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/019346 Ceased WO2000010554A2 (fr) 1998-08-25 1999-08-24 Procedes et compositions employant le vigabatrin s(+) optiquement pur

Country Status (5)

Country Link
EP (1) EP1107748A2 (fr)
JP (1) JP2003520189A (fr)
AU (1) AU5784499A (fr)
CA (1) CA2341400A1 (fr)
WO (1) WO2000010554A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007136845A2 (fr) 2006-05-19 2007-11-29 Somaxon Pharmaceuticals, Inc. Doxépine à faible dose utilisée pour le traitement de troubles du sommeil chez des patients âgés
US20100179214A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20100179215A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
CA2687118A1 (fr) 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Procedes d'utilisation de doxepine faiblement dosee pour ameliorer le sommeil
WO2008011150A1 (fr) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Méthodes destinées à améliorer la pharmacocinétique de la doxépine
US20100105614A1 (en) 2006-10-25 2010-04-29 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2008070795A2 (fr) 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Polythérapie utilisant de la doxépine à faible dose pour l'amélioration du sommeil
EP2148659A2 (fr) 2007-04-13 2010-02-03 Somaxon Pharmaceuticals, Inc. Formulations de doxépine à faible dose et procédé de préparation et d'utilisation de celle-ci
US10813898B2 (en) * 2016-03-10 2020-10-27 Orphelia Pharma Solid dosage forms of vigabatrin
CN110869003A (zh) * 2019-01-28 2020-03-06 上海奥科达生物医药科技有限公司 一种不含防腐剂的固体剂型氨己烯酸药物组合物
WO2022165352A1 (fr) * 2021-01-29 2022-08-04 Ohio State Innovation Foundation Microparticules polymères, compositions et procédés pour la libération prolongée d'un agent actif susceptible de faire l'objet d'abus
CN116120200B (zh) * 2021-11-15 2025-08-29 武汉武药科技有限公司 氨己烯酸原料药、氨己烯酸固体组合物及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595697A (en) * 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
US4621145A (en) * 1982-12-30 1986-11-04 Merrell Dow Pharmaceuticals Inc. Process for preparing 5-vinyl-2-pyrrolidinone and intermediates therefor
EP0509180A1 (fr) * 1991-04-18 1992-10-21 Merrell Dow Pharmaceuticals Inc. Utilisation d'inhibiteurs de la GABA-T pour le traitement de la schizophrenie et l'intoxication de la phencyclidine
WO2000007583A2 (fr) * 1998-08-05 2000-02-17 Brookhaven Science Associates Traitement de l'accoutumance et comportement lie a l'accoutumance

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621145A (en) * 1982-12-30 1986-11-04 Merrell Dow Pharmaceuticals Inc. Process for preparing 5-vinyl-2-pyrrolidinone and intermediates therefor
US4595697A (en) * 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
EP0509180A1 (fr) * 1991-04-18 1992-10-21 Merrell Dow Pharmaceuticals Inc. Utilisation d'inhibiteurs de la GABA-T pour le traitement de la schizophrenie et l'intoxication de la phencyclidine
WO2000007583A2 (fr) * 1998-08-05 2000-02-17 Brookhaven Science Associates Traitement de l'accoutumance et comportement lie a l'accoutumance

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ALVES N D: "Behavioral-pharmacological study of a possible analgesic effect of vigabatrin (gamma-vinil-GABA) in experimental chronic neuropathic pain", ARQUIVOS DE NEURO-PSIQUIATRIA, (MAR 1998) VOL. 56, NO. 1, PP. 150-150. PUBLISHER: ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA, C/O DR OSWALDO LANGE, CAIXA POSTAL 8877, 01065-970 SAO PAULO SP, BRAZIL. ISSN: 0004-282X., vol. 56, no. 1, March 1998 (1998-03-01), UNIV FED CEARA, TESE MESTRADO, FORTALEZA, CEARA, BRAZIL, pages 150, XP000905078 *
BENNETT GJ, XIE JK: "A peripheral mononeuropathy in rats produces disorders of pain sensation like those seen in man", PAIN, vol. 33, 1988, pages 87 - 107, XP000905585 *
BUCKETT W R: "THE INFLUENCE OF A GABA TRANSAMINASE INHIBITOR, GAMMA-VINYL GABA, ON VOLUNTARY MORPHINE CONSUMPTION IN THE RAT", PSYCHOPHARMACOLOGY,DE,SPRINGER VERLAG, BERLIN, vol. 75, no. 2, 1981, pages 214 - 216, XP000856589, ISSN: 0033-3158 *
DEWEY S L ET AL: "A PHARMACOLOGIC STRATEGY FOR THE TREATMENT OF NICOTINE ADDICTION", SYNAPSE,GB,WILEY AND SONS, CHICHESTER, vol. 31, no. 1, January 1999 (1999-01-01), pages 76 - 86, XP000856613, ISSN: 0887-4476 *
GRAM L. ET AL: "Experimental studies of the influence of vigabatrin on the GABA system.", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, (1989) 27/SUPPL. 1 (13S-17S)., XP000905099 *
MORGAN ET AL: "Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine", SYNAPSE,GB,WILEY AND SONS, CHICHESTER, vol. 18, no. 1, January 1998 (1998-01-01), pages 60 - 65, XP002127041, ISSN: 0887-4476 *
SASTRE-GARAU P; THOMAS P; BEAUSSART M; GOUDEMAND M: "Manic attack induced by a vigabatrin-clomipramine association.", ENCEPHALE, vol. 19, no. 4, 1993, pages 351 - 352, XP000911788 *
SHERIF FATHI M; TAWATI AHMED M; AHMED SALEEM S; SHARIF SULEIMAN I: "Basic aspects of GABA-transmission in alcoholism, with particular reference to GABA-transaminase.", EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 7, no. 1, 1997, pages 1 - 7, XP000911797 *
STUPPAECK C H ET AL: "THE IRREVERSIBLE GAMMA-AMINOBUTYRATE TRANSAMINASE INHIBITOR VIGABATRIN IN THE TREATMENT OF THE ALCOHOL WITHDRAWAL SYNDROME", ALCOHOL AND ALCOHOLISM. SUPPLEMENT,GB,PERGAMON, OXFORD, vol. 31, no. 1, January 1996 (1996-01-01), pages 109 - 111, XP000856593, ISSN: 1358-6173 *
WEGELIUS K ET AL: "GAMMA-VINYL GABA DECREASES VOLUNTARY ALCOHOL CONSUMPTION IN ALCOHOL-PREFERRING AA RATS", PHARMACOLOGY AND TOXICOLOGY,DK,MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN,, vol. 73, no. 3, September 1993 (1993-09-01), pages 150 - 152, XP000856621, ISSN: 0901-9928 *

Also Published As

Publication number Publication date
EP1107748A2 (fr) 2001-06-20
CA2341400A1 (fr) 2000-03-02
JP2003520189A (ja) 2003-07-02
AU5784499A (en) 2000-03-14
WO2000010554A2 (fr) 2000-03-02

Similar Documents

Publication Publication Date Title
WO2000016762A3 (fr) Procede pour reduire la dependance a la nicotine
AU3215597A (en) Method of inhibiting fibrosis with a somatostatin agonist
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
WO2001076575A3 (fr) Traitement de troubles respiratoires
CA2311356A1 (fr) Procede pour le traitement de la maladie d'alzheimer
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
ZA200202521B (en) 2'-substituted 1,1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicament and pharmaceutical preprations containing said compounds.
CA2239174A1 (fr) Nouveaux composes a effet analgesique
AU5818994A (en) Application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes
BG105096A (en) Use of optically pure(+)norcisapride for treaing apnea, bulimia and other disorders
AU5489299A (en) Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
WO2003072048A3 (fr) Soulagement des symptomes des troubles gastro-intestinaux
AU2002307049A1 (en) Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
EP1167354A3 (fr) Huperzine A racémique
WO2000071108A3 (fr) Procedes de traitement de l'asthme a l'aide de s-oxybutynine
AU6682298A (en) Use of r-nsaid's for the prevention of alzheimer's disease
WO2000051582A3 (fr) Procedes de traitement de l'apnee et de troubles de l'apnee a l'aide de r(+) ondansetron optiquement pur
NZ502495A (en) Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome
IL143985A0 (en) New use of melagatran
AU2003290015A1 (en) Mastitis treatment
GR3034665T3 (en) Antitussive composition containing an antitussive and benzydamine
WO1999065490A3 (fr) Procedes permettant de traiter l'apnee, la boulimie et d'autres troubles au moyen du norcisapride (-) optiquement pur
WO2001060343A3 (fr) Utilisation d'acide 2-methyl-thiazolidin-2,4-dicarboxylique (2-mtdc) et/ou de ses sels physiologiquement compabibles pour le traitement et/ou la prevention de cancers
WO2002060533A3 (fr) Compositions medicamenteuses a faibles effets secondaires
CA2260863A1 (fr) Traitement de troubles d'ordre psychotique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2341400

Country of ref document: CA

Ref country code: CA

Ref document number: 2341400

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 57844/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999945177

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999945177

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999945177

Country of ref document: EP